Skip to main content
Erschienen in: Journal of Cardiovascular Translational Research 2/2014

01.03.2014

Measurement of Novel Biomarkers to Predict Chronic Heart Failure Outcomes and Left Ventricular Remodeling

verfasst von: Shweta R. Motiwala, Jackie Szymonifka, Arianna Belcher, Rory B. Weiner, Aaron L. Baggish, Hanna K. Gaggin, Anju Bhardwaj, James L. Januzzi Jr.

Erschienen in: Journal of Cardiovascular Translational Research | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Myocardial remodeling is pivotal in the progression and complication of chronic heart failure (HF). We assessed serial measurement of five biomarkers with biologic links to remodeling (biglycan, secreted frizzled-related protein 3, endostatin, insulin-like growth factor binding protein 7 [IGFBP7], mimecan) in 142 patients with HF followed through 882 office visits. IGFBP7 and mimecan were most associated with events; in fully adjusted models, lower IGFBP7 concentrations across visits independently predicted fewer events (odds ratio [OR] = 0.83; 95 % confidence interval [CI] = 0.73–0.95, p = 0.01). Subjects with rising mimecan had greater decrease in left ventricular end diastolic (p = 0.07) and systolic (p = 0.01) volumes, greater increase in ejection fraction (p = 0.02), and had lowest event rates. Statistical models suggested several HF medications might lead to changes in both IGFBP7 and mimecan values. The results suggest serial measurement of IGFBP7 provides prognostic information, while changes in mimecan provide unique information regarding myocardial remodeling.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Chen, A. A., Wood, M. J., Krauser, D. G., Baggish, A. L., Tung, R., Anwaruddin, S., Picard, M. H., & Januzzi, J. L. (2006). NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy. Eur Heart J, 27(7), 839–845.PubMedCrossRef Chen, A. A., Wood, M. J., Krauser, D. G., Baggish, A. L., Tung, R., Anwaruddin, S., Picard, M. H., & Januzzi, J. L. (2006). NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy. Eur Heart J, 27(7), 839–845.PubMedCrossRef
2.
Zurück zum Zitat Januzzi, J. L., Jr., Sakhuja, R., O'Donoghue, M., Baggish, A. L., Anwaruddin, S., Chae, C. U., Cameron, R., Krauser, D. G., Tung, R., Camargo, C. A., Jr., & Lloyd-Jones, D. M. (2006). Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med, 166(3), 315–320.PubMedCrossRef Januzzi, J. L., Jr., Sakhuja, R., O'Donoghue, M., Baggish, A. L., Anwaruddin, S., Chae, C. U., Cameron, R., Krauser, D. G., Tung, R., Camargo, C. A., Jr., & Lloyd-Jones, D. M. (2006). Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med, 166(3), 315–320.PubMedCrossRef
3.
Zurück zum Zitat Januzzi, J. L., Jr., Rehman, S., Mohammed, A. A., Bhardwaj, A., Barajas, L., Barajas, J., Kim, H.-N., Baggish, A. L., Weiner, R. B., Chen, A. A., Marshall, J. E., Moore, S. A., Carlson, W. D., Lewis, G. D., Shin, J., Sullivan, D., Parks, K., Wang, T. J., Gregory, S., Uthamalingam, S., & Semigran, M. J. (2011). Use of amino-terminal Pro-B type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol, 58, 1881–1889.PubMedCrossRef Januzzi, J. L., Jr., Rehman, S., Mohammed, A. A., Bhardwaj, A., Barajas, L., Barajas, J., Kim, H.-N., Baggish, A. L., Weiner, R. B., Chen, A. A., Marshall, J. E., Moore, S. A., Carlson, W. D., Lewis, G. D., Shin, J., Sullivan, D., Parks, K., Wang, T. J., Gregory, S., Uthamalingam, S., & Semigran, M. J. (2011). Use of amino-terminal Pro-B type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol, 58, 1881–1889.PubMedCrossRef
4.
Zurück zum Zitat Baggish, A. L., van Kimmenade, R. R., & Januzzi, J. L., Jr. (2008). The differential diagnosis of an elevated amino-terminal pro-B-type natriuretic peptide level. Am J Cardiol, 101(3A), 43–48.PubMedCrossRef Baggish, A. L., van Kimmenade, R. R., & Januzzi, J. L., Jr. (2008). The differential diagnosis of an elevated amino-terminal pro-B-type natriuretic peptide level. Am J Cardiol, 101(3A), 43–48.PubMedCrossRef
5.
Zurück zum Zitat Mann, D. L., Barger, P. M., & Burkhoff, D. (2012). Myocardial recovery and the failing heart: myth, magic, or molecular target? J Am Coll Cardiol, 60(24), 2465–2472.PubMedCentralPubMedCrossRef Mann, D. L., Barger, P. M., & Burkhoff, D. (2012). Myocardial recovery and the failing heart: myth, magic, or molecular target? J Am Coll Cardiol, 60(24), 2465–2472.PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Weiner, R. B., Baggish, A. L., Chen-Tournoux, A., Marshall, J. E., Gaggin, H. K., Bhardwaj, A., Mohammed, A. A., Rehman, S. U., Barajas, L., Barajas, J., Gregory, S. A., Moore, S. A., Semigran, M. J., & Januzzi, J. L., Jr. (2013). Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study. European journal of heart failure, 15(3), 342–351.PubMedCrossRef Weiner, R. B., Baggish, A. L., Chen-Tournoux, A., Marshall, J. E., Gaggin, H. K., Bhardwaj, A., Mohammed, A. A., Rehman, S. U., Barajas, L., Barajas, J., Gregory, S. A., Moore, S. A., Semigran, M. J., & Januzzi, J. L., Jr. (2013). Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study. European journal of heart failure, 15(3), 342–351.PubMedCrossRef
7.
Zurück zum Zitat Chugh, S., Ouzounian, M., Lu, Z., Mohamed, S., Li, W., Bousette, N., Liu, P. P., & Gramolini, A. O. (2013). Pilot study identifying myosin heavy chain 7, desmin, insulin-like growth factor 7, and annexin A2 as circulating biomarkers of human heart failure. Proteomics, 13(15), 2324–2334.PubMedCrossRef Chugh, S., Ouzounian, M., Lu, Z., Mohamed, S., Li, W., Bousette, N., Liu, P. P., & Gramolini, A. O. (2013). Pilot study identifying myosin heavy chain 7, desmin, insulin-like growth factor 7, and annexin A2 as circulating biomarkers of human heart failure. Proteomics, 13(15), 2324–2334.PubMedCrossRef
8.
Zurück zum Zitat Bhardwaj, A., Rehman, S. U., Mohammed, A., Baggish, A. L., Moore, S. A., & Januzzi, J. L., Jr. (2010). Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. American heart journal, 159(4), 532–538. e531.PubMedCrossRef Bhardwaj, A., Rehman, S. U., Mohammed, A., Baggish, A. L., Moore, S. A., & Januzzi, J. L., Jr. (2010). Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. American heart journal, 159(4), 532–538. e531.PubMedCrossRef
9.
Zurück zum Zitat Ahmed, M. S., Oie, E., Vinge, L. E., Yndestad, A., Andersen, G. G., Andersson, Y., Attramadal, T., & Attramadal, H. (2003). Induction of myocardial biglycan in heart failure in rats—an extracellular matrix component targeted by AT(1) receptor antagonism. Cardiovascular research, 60(3), 557–568.PubMedCrossRef Ahmed, M. S., Oie, E., Vinge, L. E., Yndestad, A., Andersen, G. G., Andersson, Y., Attramadal, T., & Attramadal, H. (2003). Induction of myocardial biglycan in heart failure in rats—an extracellular matrix component targeted by AT(1) receptor antagonism. Cardiovascular research, 60(3), 557–568.PubMedCrossRef
10.
Zurück zum Zitat Askevold, E. T., Aukrust, P., Nymo, S., Aakhus, S., Ranheim, T., Fiane, A., Dahl, C. P., Finsen, A. V., Yndestad, A., Gullestad, L., Latini, R., Masson, S., Tavazzi, L., & Ueland, T. (2012). GISSI-HF Investigators. Abstract 18191: secreted frizzled related protein 3, an inhibitor of Wnt-signaling, is upregulated in clinical and experimental heart failure. Circulation, 126(21 Supplement), A18191. Askevold, E. T., Aukrust, P., Nymo, S., Aakhus, S., Ranheim, T., Fiane, A., Dahl, C. P., Finsen, A. V., Yndestad, A., Gullestad, L., Latini, R., Masson, S., Tavazzi, L., & Ueland, T. (2012). GISSI-HF Investigators. Abstract 18191: secreted frizzled related protein 3, an inhibitor of Wnt-signaling, is upregulated in clinical and experimental heart failure. Circulation, 126(21 Supplement), A18191.
11.
Zurück zum Zitat Isobe, K., Kuba, K., Maejima, Y., Suzuki, J., Kubota, S., & Isobe, M. (2010). Inhibition of endostatin/collagen XVIII deteriorates left ventricular remodeling and heart failure in rat myocardial infarction model. Circulation journal : official journal of the Japanese Circulation Society, 74(1), 109–119.CrossRef Isobe, K., Kuba, K., Maejima, Y., Suzuki, J., Kubota, S., & Isobe, M. (2010). Inhibition of endostatin/collagen XVIII deteriorates left ventricular remodeling and heart failure in rat myocardial infarction model. Circulation journal : official journal of the Japanese Circulation Society, 74(1), 109–119.CrossRef
12.
Zurück zum Zitat Gramolini, A. O., Kislinger, T., Alikhani-Koopaei, R., Fong, V., Thompson, N. J., Isserlin, R., Sharma, P., Oudit, G. Y., Trivieri, M. G., Fagan, A., Kannan, A., Higgins, D. G., Huedig, H., Hess, G., Arab, S., Seidman, J. G., Seidman, C. E., Frey, B., Perry, M., Backx, P. H., Liu, P. P., MacLennan, D. H., & Emili, A. (2008). Comparative proteomics profiling of a phospholamban mutant mouse model of dilated cardiomyopathy reveals progressive intracellular stress responses. Molecular & cellular proteomics : MCP, 7(3), 519–533.CrossRef Gramolini, A. O., Kislinger, T., Alikhani-Koopaei, R., Fong, V., Thompson, N. J., Isserlin, R., Sharma, P., Oudit, G. Y., Trivieri, M. G., Fagan, A., Kannan, A., Higgins, D. G., Huedig, H., Hess, G., Arab, S., Seidman, J. G., Seidman, C. E., Frey, B., Perry, M., Backx, P. H., Liu, P. P., MacLennan, D. H., & Emili, A. (2008). Comparative proteomics profiling of a phospholamban mutant mouse model of dilated cardiomyopathy reveals progressive intracellular stress responses. Molecular & cellular proteomics : MCP, 7(3), 519–533.CrossRef
13.
Zurück zum Zitat Dinh, W, Coll Barroso, M, Futh, R, Lankisch, M, Klein, R, Gulker, J, Bufe, A, Scheffold, T, Nickl, N, Seyfarth, M. 92012) Abstract P1288: Serum insulin like growth factor-i and its binding protein-7: novel promising biomarker in heart failure with preserved ejection fraction. Clinical Research in Cardiology; 101(Supplement 1). Dinh, W, Coll Barroso, M, Futh, R, Lankisch, M, Klein, R, Gulker, J, Bufe, A, Scheffold, T, Nickl, N, Seyfarth, M. 92012) Abstract P1288: Serum insulin like growth factor-i and its binding protein-7: novel promising biomarker in heart failure with preserved ejection fraction. Clinical Research in Cardiology; 101(Supplement 1).
14.
Zurück zum Zitat Petretto, E., Sarwar, R., Grieve, I., Lu, H., Kumaran, M. K., Muckett, P. J., Mangion, J., Schroen, B., Benson, M., Punjabi, P. P., Prasad, S. K., Pennell, D. J., Kiesewetter, C., Tasheva, E. S., Corpuz, L. M., Webb, M. D., Conrad, G. W., Kurtz, T. W., Kren, V., Fischer, J., Hubner, N., Pinto, Y. M., Pravenec, M., Aitman, T. J., & Cook, S. A. (2008). Integrated genomic approaches implicate osteoglycin (Ogn) in the regulation of left ventricular mass. Nat Genet, 40(5), 546–552.PubMedCentralPubMedCrossRef Petretto, E., Sarwar, R., Grieve, I., Lu, H., Kumaran, M. K., Muckett, P. J., Mangion, J., Schroen, B., Benson, M., Punjabi, P. P., Prasad, S. K., Pennell, D. J., Kiesewetter, C., Tasheva, E. S., Corpuz, L. M., Webb, M. D., Conrad, G. W., Kurtz, T. W., Kren, V., Fischer, J., Hubner, N., Pinto, Y. M., Pravenec, M., Aitman, T. J., & Cook, S. A. (2008). Integrated genomic approaches implicate osteoglycin (Ogn) in the regulation of left ventricular mass. Nat Genet, 40(5), 546–552.PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Voss, S, Nef, H, Szardien, S, Troidl, C, Kojonazarov, B, Visser, D, Hoffmann, J, Willmer, M, Hamm, C. W, Moellmann, H. 92012) Abstract 2014: Osteoglycin deficiency leads to maladaptive remodeling and severe cardiac dysfunction in a mouse model of cardiac hypertrophy. Eur Heart J; 33(Supplement 1):342. Voss, S, Nef, H, Szardien, S, Troidl, C, Kojonazarov, B, Visser, D, Hoffmann, J, Willmer, M, Hamm, C. W, Moellmann, H. 92012) Abstract 2014: Osteoglycin deficiency leads to maladaptive remodeling and severe cardiac dysfunction in a mouse model of cardiac hypertrophy. Eur Heart J; 33(Supplement 1):342.
16.
Zurück zum Zitat Lang, R. M., Bierig, M., Devereux, R. B., Flachskampf, F. A., Foster, E., Pellikka, P. A., Picard, M. H., Roman, M. J., Seward, J., Shanewise, J., Solomon, S., & Spencer, K. T. (2006). St John Sutton M. Stewart W. Recommendations for chamber quantification. Eur J Echocardiogr, 7(2), 79–108.PubMedCrossRef Lang, R. M., Bierig, M., Devereux, R. B., Flachskampf, F. A., Foster, E., Pellikka, P. A., Picard, M. H., Roman, M. J., Seward, J., Shanewise, J., Solomon, S., & Spencer, K. T. (2006). St John Sutton M. Stewart W. Recommendations for chamber quantification. Eur J Echocardiogr, 7(2), 79–108.PubMedCrossRef
17.
Zurück zum Zitat Brandan, E., Cabello-Verrugio, C., & Vial, C. (2008). Novel regulatory mechanisms for the proteoglycans decorin and biglycan during muscle formation and muscular dystrophy. Matrix Biol, 27(8), 700–708.PubMedCrossRef Brandan, E., Cabello-Verrugio, C., & Vial, C. (2008). Novel regulatory mechanisms for the proteoglycans decorin and biglycan during muscle formation and muscular dystrophy. Matrix Biol, 27(8), 700–708.PubMedCrossRef
18.
Zurück zum Zitat Fadic, R., Mezzano, V., Alvarez, K., Cabrera, D., Holmgren, J., & Brandan, E. (2006). Increase in decorin and biglycan in Duchenne Muscular Dystrophy: role of fibroblasts as cell source of these proteoglycans in the disease. J Cell Mol Med, 10(3), 758–769.PubMedCrossRef Fadic, R., Mezzano, V., Alvarez, K., Cabrera, D., Holmgren, J., & Brandan, E. (2006). Increase in decorin and biglycan in Duchenne Muscular Dystrophy: role of fibroblasts as cell source of these proteoglycans in the disease. J Cell Mol Med, 10(3), 758–769.PubMedCrossRef
19.
Zurück zum Zitat Hoang, B., Moos, M., Jr., Vukicevic, S., & Luyten, F. P. (1996). Primary structure and tissue distribution of FRZB, a novel protein related to Drosophila frizzled, suggest a role in skeletal morphogenesis. J Biol Chem, 271(42), 26131–26137.PubMedCrossRef Hoang, B., Moos, M., Jr., Vukicevic, S., & Luyten, F. P. (1996). Primary structure and tissue distribution of FRZB, a novel protein related to Drosophila frizzled, suggest a role in skeletal morphogenesis. J Biol Chem, 271(42), 26131–26137.PubMedCrossRef
20.
Zurück zum Zitat Svensson, A., Norrby, M., Libelius, R., & Tagerud, S. (2008). Secreted frizzled related protein 1 (Sfrp1) and Wnt signaling in innervated and denervated skeletal muscle. J Mol Histol, 39(3), 329–337.PubMedCrossRef Svensson, A., Norrby, M., Libelius, R., & Tagerud, S. (2008). Secreted frizzled related protein 1 (Sfrp1) and Wnt signaling in innervated and denervated skeletal muscle. J Mol Histol, 39(3), 329–337.PubMedCrossRef
21.
Zurück zum Zitat Tufan, A. C., Daumer, K. M., & Tuan, R. S. (2002). Frizzled-7 and limb mesenchymal chondrogenesis: effect of misexpression and involvement of N-cadherin. Dev Dyn, 223(2), 241–253.PubMedCrossRef Tufan, A. C., Daumer, K. M., & Tuan, R. S. (2002). Frizzled-7 and limb mesenchymal chondrogenesis: effect of misexpression and involvement of N-cadherin. Dev Dyn, 223(2), 241–253.PubMedCrossRef
22.
Zurück zum Zitat Glenjen, N., Mosevoll, K. A., & Bruserud, O. (2002). Serum levels of angiogenin, basic fibroblast growth factor and endostatin in patients receiving intensive chemotherapy for acute myelogenous leukemia. Int J Cancer, 101(1), 86–94.PubMedCrossRef Glenjen, N., Mosevoll, K. A., & Bruserud, O. (2002). Serum levels of angiogenin, basic fibroblast growth factor and endostatin in patients receiving intensive chemotherapy for acute myelogenous leukemia. Int J Cancer, 101(1), 86–94.PubMedCrossRef
23.
Zurück zum Zitat Miyashita, M., Tajiri, T., Yanagi, K., Shimizu, T., Futami, R., Sasajima, K., & Tokunaga, A. (2003). Serum levels of vascular endothelial growth factor, basic fibroblast growth factor and endostatin in human metastatic liver tumors. Hepatogastroenterology, 50(50), 308–309.PubMed Miyashita, M., Tajiri, T., Yanagi, K., Shimizu, T., Futami, R., Sasajima, K., & Tokunaga, A. (2003). Serum levels of vascular endothelial growth factor, basic fibroblast growth factor and endostatin in human metastatic liver tumors. Hepatogastroenterology, 50(50), 308–309.PubMed
24.
Zurück zum Zitat Gu, X. S., Lei, J. P., Shi, J. B., Lian, W. L., Yang, X., Zheng, X., & Qin, Y. W. (2011). Mimecan is involved in aortic hypertrophy induced by sinoaortic denervation in rats. Mol Cell Biochem, 352(1–2), 309–316.PubMedCrossRef Gu, X. S., Lei, J. P., Shi, J. B., Lian, W. L., Yang, X., Zheng, X., & Qin, Y. W. (2011). Mimecan is involved in aortic hypertrophy induced by sinoaortic denervation in rats. Mol Cell Biochem, 352(1–2), 309–316.PubMedCrossRef
25.
Zurück zum Zitat Jazbutyte, V., Fiedler, J., Kneitz, S., Galuppo, P., Just, A., Holzmann, A., Bauersachs, J., & Thum, T. (2012). MicroRNA-22 increases senescence and activates cardiac fibroblasts in the aging heart. Age (Dordr), 35(3), 747–762.CrossRef Jazbutyte, V., Fiedler, J., Kneitz, S., Galuppo, P., Just, A., Holzmann, A., Bauersachs, J., & Thum, T. (2012). MicroRNA-22 increases senescence and activates cardiac fibroblasts in the aging heart. Age (Dordr), 35(3), 747–762.CrossRef
26.
Zurück zum Zitat Cavallari, L. H., & Limdi, N. A. (2009). Warfarin pharmacogenomics. Curr Opin Mol Ther, 11(3), 243–251.PubMed Cavallari, L. H., & Limdi, N. A. (2009). Warfarin pharmacogenomics. Curr Opin Mol Ther, 11(3), 243–251.PubMed
27.
Zurück zum Zitat Grzymala-Lubanski, B., Sjalander, S., Renlund, H., Svensson, P. J., & Sjalander, A. (2013). Computer aided warfarin dosing in the Swedish national quality registry AuriculA — algorithmic suggestions are performing better than manually changed doses. Thromb Res, 131(2), 130–134.PubMedCrossRef Grzymala-Lubanski, B., Sjalander, S., Renlund, H., Svensson, P. J., & Sjalander, A. (2013). Computer aided warfarin dosing in the Swedish national quality registry AuriculA — algorithmic suggestions are performing better than manually changed doses. Thromb Res, 131(2), 130–134.PubMedCrossRef
28.
Zurück zum Zitat Motiwala, S. R., Szymonifka, J., Belcher, A., Weiner, R. B., Baggish, A. L., Sluss, P., Gaggin, H. K., Bhardwaj, A., & Januzzi, J. L. (2013). Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Eur J Heart Fail, 15(10), 1157–1163.PubMedCrossRef Motiwala, S. R., Szymonifka, J., Belcher, A., Weiner, R. B., Baggish, A. L., Sluss, P., Gaggin, H. K., Bhardwaj, A., & Januzzi, J. L. (2013). Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Eur J Heart Fail, 15(10), 1157–1163.PubMedCrossRef
29.
Zurück zum Zitat van Kimmenade, R. R., & Januzzi, J. L., Jr. (2012). Emerging biomarkers in heart failure. Clin Chem, 58(1), 127–138.PubMedCrossRef van Kimmenade, R. R., & Januzzi, J. L., Jr. (2012). Emerging biomarkers in heart failure. Clin Chem, 58(1), 127–138.PubMedCrossRef
30.
Zurück zum Zitat Januzzi, J. L., Jr. (2013). Natriuretic peptides as biomarkers in heart failure. J Investig Med, 61(6), 950–955.PubMed Januzzi, J. L., Jr. (2013). Natriuretic peptides as biomarkers in heart failure. J Investig Med, 61(6), 950–955.PubMed
Metadaten
Titel
Measurement of Novel Biomarkers to Predict Chronic Heart Failure Outcomes and Left Ventricular Remodeling
verfasst von
Shweta R. Motiwala
Jackie Szymonifka
Arianna Belcher
Rory B. Weiner
Aaron L. Baggish
Hanna K. Gaggin
Anju Bhardwaj
James L. Januzzi Jr.
Publikationsdatum
01.03.2014
Verlag
Springer US
Erschienen in
Journal of Cardiovascular Translational Research / Ausgabe 2/2014
Print ISSN: 1937-5387
Elektronische ISSN: 1937-5395
DOI
https://doi.org/10.1007/s12265-013-9522-8

Weitere Artikel der Ausgabe 2/2014

Journal of Cardiovascular Translational Research 2/2014 Zur Ausgabe

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.